drugset / Trial / NCT05305833
Stem Cells and Stromal Vascular Fraction for Temporomandibular Joint Disease
RandomizedParallel-groupSingle-blindTreatment
Summary
It will be evaluate the safety of mesenchymal stem cells and adipose tissue derived stromal vascular fraction (SVF) in temporomandibular joint disease cases.
Timeline
- Start
- 2021-10-01
- Primary completion
- 2022-12-01
- Completion
- 2023-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rexlemestrocel-L | Cell therapy | — | — |